Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus LAMIVUDINE NEVIRAPINE AND STAVUDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus LAMIVUDINE NEVIRAPINE AND STAVUDINE.
EMTRICITABINE vs LAMIVUDINE, NEVIRAPINE, AND STAVUDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Lamivudine and stavudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV-1 reverse transcriptase by incorporating into viral DNA and causing chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing a conformational change and inhibiting its activity.
200 mg orally once daily, typically in combination with other antiretroviral agents.
Lamivudine 150 mg, nevirapine 200 mg, and stavudine 30 mg (or 40 mg if weight ≥60 kg) orally twice daily for HIV treatment in adults.
None Documented
None Documented
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Lamivudine: 5-7 hours (prolonged in renal impairment). Nevirapine: 25-30 hours (terminal, autoinduction reduces early half-life; significant accumulation). Stavudine: 1.0-1.6 hours (short; prolonged in renal impairment).
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Lamivudine: ~71% excreted unchanged in urine (glomerular filtration and active tubular secretion). Nevirapine: ~81% excreted in urine as glucuronide conjugates, <5% unchanged; ~10% in feces. Stavudine: ~40% excreted unchanged in urine (active tubular secretion), with remainder as metabolites.
Category C
Category A/B
Antiretroviral, NRTI
NRTI